Based on these facts, this study aimed to measure time-series changes in soluble EphA2 released from CRC cell lines and to measure soluble EphA2 in serum samples from patients with CRC to examine the relationship between EphA2 and the clinical characteristics of these patients. Here, EPHA2 is linked to colorectal carcinoma.